MINNEAPOLIS (BUSINESS WIRE) Jul 15, 2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Companyâs Board of Directors. Amy Burroughs, President and CEO of Cleave Therapeutics, brings over 20 years of experience in business and commercial development, strategy and leadership in the pharmaceutical industry. Dr. Charles Semba, Chief Medical Officer of Eluminex Biosciences, has over 20 years of drug-development experience in high growth public and private therapeutics companies and serves on the faculty of Vascular/Interventional Radiology at Stanford University.
Press release content from Business Wire. The AP news staff was not involved in its creation.
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results
May 5, 2021 GMT
MINNEAPOLIS (BUSINESS WIRE) May 5, 2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2021. DiaMedica will host a conference call Thursday, May 6, 2021, at 7:00 a.m. Central Time to discuss its business update and first quarter financial results.
Clinical Developments
IND Submitted
Initiation of Phase 2/3 Trial of DM199 in AIS in Summer 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke
March 9, 2021 GMT
MINNEAPOLIS (BUSINESS WIRE) Mar 9, 2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will host a key opinion leader (KOL) webinar on DM199, the Company’s lead asset for the treatment of Acute Ischemic Stroke (AIS), on Friday, March 19, 2021 at 12:00pm Eastern Time.
The webinar will feature presentations by KOLs Scott Kasner, M.D., University of Pennsylvania, and Paolo Madeddu, M.D., University of Bristol, who will discuss the current treatment landscape and unmet medical need in treating patients with AIS and the rationale for the treatment of stroke and stroke recurrence with DM199. Drs. Kasner and Madeddu will be available to answ